[ INVESTOR / ENTREPRENEUR / FOUNDER ]

Capital for the future of health.

Lipin Zeng founds, integrates and invests in pharmaceutical, botanical and digital-health companies, connecting China’s traditional-medicine industry with U.S. markets since 1994.

View portfolio → Pitch an opportunity
30+
YEARS OPERATING
10+
COMPANIES
3
MARKETS · CN HK US

[ FOCUS ]

Focus areas

Where Lipin Zeng founds companies, partners and allocates capital.

PHARMA

Pharmaceutical integration

Consolidating regional manufacturers into scaled groups ready for the public markets.

BOTANICALS

Botanical value chains

Seed-to-shelf control of high-value botanicals such as Yunnan notoginseng (Sanqi).

SCIENCE

Science & regulation

GRAS determinations and clinical research that bring TCM ingredients up to U.S. standards.

DIGITAL

Digital health & AI

Fulfillment, practice software and AI decision support built for practitioners.

[ U.S. VENTURES ]

Building in America

Since 2018 his focus has been the United States: evidence-based botanicals, practitioner fulfillment, and software for the practice of traditional medicine.

The DirectCM website for practitioners
FOUNDERU.S. · SINCE 2020

DirectCM

A nationwide supplement and TCM delivery service launched during the COVID-19 pandemic, so practitioners could keep getting supplies to their patients.

  • Warehouses3
  • DeliveryNext day, nationwide
  • Classic TCM formulas50+
  • Medical members30,000+ · expected 50,000 by year-end
The MyCare app on a phone
FOUNDERU.S. · DIGITAL HEALTH

MyCare LAUNCH 2027

Practice-management software for TCM practitioners covering scheduling, patient records and insurance claims, with telehealth primary and urgent care through a leading virtual-care partner.

  • Pre-registered practitioners30,000
  • Partner clinicians6,000
  • Insurance plans600+
  • CoverageAll 50 states
Traditional Chinese herbs connected by a glowing AI network
FOUNDERAI · IN TESTING

TCMInfo AI

An AI system trained on the TCM literature that provides pattern analysis and personalized medication guidance. The test version passed WeChat’s review and is in online testing.

Bright botanical research laboratory at Farlong Nutraceutical
FOUNDERU.S. · SINCE 2018

Farlong Nutraceutical

Botanical ingredients taken through U.S. regulatory pathways, with several GRAS determinations and clinical research. In April 2024 Farlong began a cancer-supplement research collaboration with City of Hope.

[ CAPITAL MARKETS ]

Path to the public markets

The SEC declared Farlong USA’s IPO registration statement effective in 2026. The company plans to complete its initial public offering in 2027, to expand the business and strengthen its brand.

This website is for information only. It is not an offer to sell, or a solicitation of an offer to buy, any securities. Any offering will be made only by means of a prospectus.

  1. 2018U.S. program beginsGRAS and clinical research for TCM ingredients
  2. 2026Registration effectiveSEC declares the IPO registration statement effective
  3. 2027Planned IPOInitial public offering of Farlong USA

[ PORTFOLIO ]

Portfolio

Companies founded, integrated or backed by Lipin Zeng across three decades and three markets.

COMPANYSECTORREGIONROLE
Yunnan Panlong Yunhai Pharmaceutical GroupPharmaceuticalsChina / HKFounder
Yunnan Chuangli Equity Investment FundPrivate equityChinaFounder
Yunnan Chuangli Biopharmaceutical GroupBiopharmaChinaFounder
Yunnan Sanqi TechnologyBotanical value chainChinaFounder
Dali · Weimen · Kunming Longjin · Yunnan Salt ChemicalPharma / chemicalsChinaInvestor
Farlong USA · LongFar Hong Kong PharmaceuticalBotanical ingredientsU.S. / HKFounder
DirectCMPractitioner fulfillmentU.S.Founder
MyCare · TCMInfo AIDigital health / AIU.S.Founder

Weimen Pharmaceutical is listed on China’s New Third Board.

[ TRACK RECORD ]

Track record

  1. 1990B.Med., Beijing University of Chinese Medicine; moves to Hong Kong
  2. 1994Founds Yunnan Panlong Yunhai Pharmaceutical Group and introduces the Detox Beauty Capsule
  3. 2014Recognized by Los Angeles County Mayor Michael D. Antonovich for contributions to the health-food sector
  4. 2018Begins U.S. regulatory program: GRAS and clinical research
  5. 2020Launches DirectCM nationwide next-day TCM fulfillment
  6. 2024City of Hope research collaboration; TCMInfo AI enters testing
  7. 2026SEC declares the Farlong USA IPO registration statement effective
  8. 2027Planned IPO and MyCare launch PLANNED
Portrait of Lipin Zeng

[ BIO ]

A physician turned entrepreneur, with a Bachelor of Medicine from Beijing University of Chinese Medicine and an MBA.

Lipin Zeng graduated in 1990 and moved to Hong Kong to start his first business. In 1994 he founded Yunnan Panlong Yunhai Pharmaceutical Group, developing its detoxification, rejuvenation and health-maintenance formulations and helping revitalize the ethnic medicine of Yunnan.

He went on to integrate the province’s pharmaceutical resources through Farlong USA, LongFar Hong Kong Pharmaceutical, Yunnan Chuangli Biopharmaceutical Group and the Yunnan Chuangli Equity Investment Fund, and built Yunnan Sanqi Technology into a full-industry-chain notoginseng enterprise.

EDUCATION
B.Med. · MBA
MARKETS
China · Hong Kong · U.S.

[ ON THE RECORD ]

In the industry

Lipin Zeng at the 11th Conference of Chinese Pharmacists
CONFERENCE11th Conference of Chinese Pharmacists
Lipin Zeng at the opening of an exhibition of Chinese medicine artifacts in 2017
2017Opening ceremony, Prof. Paul U. Unschuld’s Collection of Valuable Chinese Medicine Artifacts

[ CONTACT ]

Building something in health?

Founders, co-investors and partners: share a short overview and the team will follow up.